About this item:

85 Views | 38 Downloads

Author Notes:

Stephen Robinson, Email: strob@gatech.edu

We thank the NIH (R21 AG061687 and R01 HL136141) for funding. The authors also gratefully acknowledge funding by the Defense Threat Reduction Agency (DTRA) under Space and Naval Warfare Systems Center Pacific (SSC PACIFIC) Contract No. N66001-13-C-2027. The content is solely the responsibility of the authors and does not necessarily represent the official views of the awarding agency. This material is also based upon work supported by the National Science Foundation Graduate Research Fellowship Program to J.C. and E.P. (DGE-1650044

Subject:

Research Funding:

NIH (R21 AG061687 and R01 HL136141)

Defense Threat Reduction Agency (DTRA) under Space and Naval Warfare Systems Center Pacific (SSC PACIFIC) Contract No. N66001-13-C-2027.

National Science Foundation Graduate Research Fellowship Program to J.C. and E.P. (DGE-1650044).

Keywords:

  • Science & Technology
  • Technology
  • Engineering, Biomedical
  • Materials Science, Biomaterials
  • Engineering
  • Materials Science
  • fibrinolysis
  • phenotypic assay
  • aqueous two-phase system
  • fibrin
  • wound healing
  • fibrosis

Aqueous two-phase deposition and fibrinolysis of fibroblast-laden fibrin micro-scaffolds

Tools:

Journal Title:

BIOFABRICATION

Volume:

Volume 13, Number 3

Publisher:

Type of Work:

Article | Post-print: After Peer Review

Abstract:

This paper describes printing of microscale fibroblast-laden matrices using an aqueous two-phase approach that controls thrombin-mediated enzymatic crosslinking of fibrin. Optimization of aqueous two-phase formulations enabled polymerization of consistent sub-microliter volumes of cell-laden fibrin. When plasminogen was added to these micro-scaffolds, the primary normal human lung fibroblasts converted it to plasmin, triggering gradual degradation of the fibrin. Time-lapse live-cell imaging and automated image analysis provided readouts of time to degradation of 50% of the scaffold as well as maximum degradation rate. The time required for degradation decreased linearly with cell number while it increased in a dose-dependent manner upon addition of TGF-β1. Fibroblasts isolated from idiopathic pulmonary fibrosis patients showed similar trends with regards to response to TGF-β1 stimulation. Addition of reactive oxygen species (ROS) slowed fibrinolysis but only in the absence of TGF-β1, consistent with published studies demonstrating that pro-fibrotic cellular phenotypes induced by TGF-β1 are mediated, at least in part, through increased production of ROS. FDA-approved and experimental anti-fibrosis drugs were also tested for their effects on fibrinolysis rates. Given the central role of fibrinolysis in both normal and pathogenic wound healing of various tissues, the high-throughput cell-mediated fibrinolysis assay described has broad applicability in the study of many different cell types and diseases. Furthermore, aqueous two-phase printing of fibrin addresses several current limitations of fibrin bio-inks, potentially enabling future applications in tissue engineering and in vitro models.

Copyright information:

This is an Open Access work distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (https://creativecommons.org/licenses/by-nc-nd/4.0/rdf).
Export to EndNote